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Abstract   43 
Hypoparathyroidism is a rare disease in children that occurs as a result of autoimmune 44 
destruction of the parathyroid glands, a defect in parathyroid gland development or secondary 45 
to physical parathyroid gland disturbance. Typical symptoms of hypoparathyroidism present as 46 
hypocalcaemia and hyperphosphatemia due to decreased parathyroid hormone secretion and 47 
may lead to nerve and muscles disturbances resulting in clinical manifestation of tetany, 48 
arrhythmias and epilepsy. Currently, there is no conventional hormone replacement treatment 49 
for hypoparathyroidism and therapeutic approaches include normalising mineral levels using 50 
an oral calcium supplement and active forms of vitamin D. We present the case of a 10-year-51 
old girl with primary hypoparathyroidism who had no prior history of autoimmune disorders, 52 
but who subsequently developed systemic lupus erythematosus.  53 
 54 
Keywords: primary hypoparathyroidism, hypocalcaemia, hyperphosphatemia, parathyroid 55 
hormone, systemic lupus erythematosus, autoimmune polyglandular syndrome. 56 
5 
 
Background  57 
Hypoparathyroidism is a rare endocrine disease in children caused by parathyroid hormone 58 
(PTH) deficiency or resistance to PTH [1]. Primary hypoparathyroidism may occur as a result 59 
of either autoimmune destruction of the parathyroid glands, a congenital defect of parathyroid 60 
gland development as in DiGeorge 22q11.2 deletion syndrome, mutations in the calcium-61 
sensing receptor gene, damage to the parathyroids during surgery, most commonly in the 62 
course of thyroidectomy, or following radiation treatment of the neck [2-4]. The typical 63 
manifestations of the disease present when all four parathyroid glands are affected and include 64 
hypocalcaemia, hyperphosphatemia and low serum PTH concentrations. The serum mineral 65 
abnormalities affect nerve and muscle functions leading to tetany, arrhythmias and seizures. 66 
There is no conventional hormone replacement therapy and the management of 67 
hypocalcaemia and hyperphosphatemia involves an oral calcium supplement and active forms 68 
of vitamin D [3].   69 
Here, we present the case of a 10-year-old girl with primary hypoparathyroidism who had no 70 
prior history of autoimmune disorders, but who developed systemic lupus erythematosus 71 
(SLE) a few months after her diagnosis of hypoparathyroidism. To date, there are only a few 72 
reported cases of the coexistence of hypoparathyroidism and SLE [5].    73 
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Case presentation  74 
A 10-year-old Polish female initially presented to the Department of Paediatric Neurology 75 
and Rehabilitation with convulsions. Following a confirmation of hypocalcaemia she was 76 
referred to the Department of Paediatrics, Endocrinology, Diabetology with Cardiology with 77 
suspected hypoparathyroidism. The patient had no history of mucocutaneous candidiasis and 78 
no history suggesting an endocrine or autoimmune disorder in her family. Her mental 79 
development was normal. Her weight was 35 kg (6th percentile of 10-year-old females) and 80 
her height was 141 cm (50th percentile of 10-year-old females). She was in early puberty at 81 
stage 2 on the Tanner scale, based on breast development. 82 
The patient was admitted to our department severely unwell with drowsiness and confusion. 83 
The physical examination revealed a whole body rash that was attributed to an allergic 84 
reaction to oxcarbazepine that was being used for the treatment of convulsions. She had no 85 
features of ectodermal dystrophy or any signs of primary adrenal insufficiency. 86 
Hypoparathyroidism was diagnosed based on very low PTH levels at <3 pg/mL (reference 87 
range, 10-69 pg/mL), low total serum calcium levels at 0.80 mmol/L (reference range, 2.19-88 
2.69 mmol/L) (Figure 1) and high plasma phosphate levels at 11.8 mg/dL (reference range, 89 
3.4-6.2 mg/dL) (Figure 1). Alkaline phosphatase levels and serum magnesium concentrations 90 
were normal. Total serum vitamin D was low at 35 nmol/L (reference range, 50-150 nmol/L). 91 
Urinary calcium levels were lower than normal at admission. 92 
Hormone analysis showed normal thyroid function (thyroid-stimulating hormone at 1.76 93 
IU/L, reference range, 0.28-4.3 IU/L; free T4 at 23 pmol/L, reference range, 14-22 pmol/L). 94 
Adrenal function tests were within the normal range (cortisol at 347.3 nmol/L; 95 
adrenocorticotropic hormone at 2.8 pmol/L; adequate peak cortisol level of 749.5 nmol/L 96 
after 250 µg of tetracosactin by intravenous injection). Markers for specific for autoimmune 97 
diseases including antibodies against interferon (IFN)-ω, 21-hydroxylase, 17-α-hydroxylase, 98 
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the calcium-sensing receptor, the acetylcholine receptor, and tissue transglutaminase were not 99 
detected (Table 1). Autoantibodies associated with autoimmune thyroid disease and type 1 100 
diabetes were also undetectable (Table 1). In blood morphology analysis, there were 101 
periodical findings indicating anaemia, leucopaenia and hypoalbuminaemia in biochemical 102 
tests.  103 
Ultrasonography revealed a slightly enlarged spleen without any features of nephrocalcinosis 104 
and no parathyroid pathology. Echocardiography (ECG) did not reveal any heart defect. 105 
However, effusion in the pericardium was observed coinciding with the fever and elevated 106 
inflammatory markers. Long QTc (over 0.5 seconds) was recorded in the ECG. A bone 107 
densitometry scan showed normal values for bone mass density of the spine L2-L4 (Z-score 108 
+0.5) and for total body less head (Z-score +0.1). There was no ectopic calcification observed 109 
in magnetic resonance imaging (MRI) of the head. A positron emission tomography-magnetic 110 
resonance imaging (PET-MRI) scan of the whole body did not reveal any other pathologies. 111 
Electroencephalography was abnormal with pathological changes localised in temporal areas 112 
on both sides during activity and generalised paroxysmal patterns during sleep. However, 113 
there were no more epileptic seizures during clinical observation.  114 
The patient was started on intravenous calcium gluconate at 5.5 g elemental calcium/day 115 
along with oral calcium carbonate (0.8 g elemental calcium/day), vitamin D (2000 IU/day) 116 
and the synthetic precursor of the active form of vitamin D3, alfacalcidol (2 µg/day). 117 
Hyperphosphatemia was initially treated with a diet low in phosphates. She was also treated 118 
with valproic acid for epilepsy, metoprolol for long QTc, and hydrocortisone for the first nine 119 
days to reduce her allergy symptoms. The patient’s condition improved and her total serum 120 
calcium levels increased, although they remained below the normal range (Figure 1). 121 
After fourteen days of hospitalisation, the patient developed a fever with pneumonia and 122 
pericardial effusion together with increased inflammatory markers in laboratory tests. C-123 
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reactive protein increased significantly from 30.2 to 1497 nmol/L (reference range, 0-47 124 
nmol/L). She was treated with antibiotics, although the blood cultures returned negative 125 
results. There was no evidence of either viral infections including HIV, B19 parvovirus, 126 
influenza or of zoonoses or tuberculosis. Furthermore, neoplastic disease was excluded 127 
following a bone marrow biopsy. During the course of a chest infection, her total serum 128 
calcium levels dropped to below 2 mmol/L. After three weeks of hospitalisation and with a 129 
high plasma phosphate level of 9.20 mg/dL, she was given sevelamer (initial dose 2.4 g/day), 130 
a phosphate-binding medication, to reduce hyperphosphatemia (Figure 1). Finally, the patient 131 
was discharged on regular oral calcium carbonate (3.6 g elemental calcium/day), sevelamer 132 
(4.8 g/day) and alphacalcidol (1 µg/day). 133 
Taken together, the clinical symptoms, laboratory test results and the criteria of the American 134 
College of Rheumatology for SLE, in particular, epilepsy, leucopaenia, pericardial effusion 135 
and anti-nuclear antibodies, the patient was diagnosed with SLE. She was treated 136 
subsequently with chloroquine phosphate and oral prednisone (5 mg/day). This treatment 137 
unexpectedly improved the patient’s calcium and phosphate levels (Figure 1) and allowed a 138 
reduction in the doses of calcium, sevelamer and vitamin D. During monthly follow up visits, 139 
the patient’s serum calcium and phosphate levels continued to normalise (Figure 1), albeit 140 
with episodes of hypercalcaemia. 141 
At four months follow-up, the patient was re-evaluated for anti-IFN-ω and anti-21-hydroylase 142 
antibodies. She was found positive for IFN-ω antibodies (antibody index 21.4, reference range 143 
<5.0) (Table 1). To further investigate the cause of the hypoparathyroidism, we evaluated 144 
genetic mutations that are typically connected with the disease.  Mutational analysis of genes 145 
encoding the calcium-sensing receptor (CASR), guanine nucleotide-binding protein subunit 146 
alpha-11 (GNA11), PTH (PTH), glial cells missing transcription factor 2 (GCM2), 147 
autoimmune regulator (AIRE) and GATA binding protein 3 (GATA3) were all negative. In 148 
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addition, whole exome sequence variants in established disease genes and candidate variants 149 
in genes not yet associated with disease were negative. However, it revealed a heterozygous 150 
microdeletion in chromosome 15q11.2, inherited from the father and not reported previously 151 




The combination of hypoparathyroidism and SLE is extremely rare therefore the underlying 154 
causes and significance of these diseases occurring in conjunction is intriguing. 155 
Hypoparathyroidism can be caused by several factors including autoimmunity affecting the 156 
parathyroid glands, damage to parathyroid glands and genetic mutations such as DiGeorge 157 
syndrome or calcium-sensing receptor-activating mutations [6, 7]. In this case, secondary 158 
hypoparathyroidism could immediately be discounted as the patient had had no surgery or 159 
trauma to the neck or parathyroid glands. The patient did not display symptoms associated 160 
with DiGeorge syndrome nor with calcium-sensing receptor-activating mutations. This was 161 
supported by mutational analysis, which did not reveal mutations in the CASR gene.  In view 162 
of the above and the association with SLE, it was expected that hypoparathyroidism in this 163 
patient had an underlying autoimmune origin. 164 
An autoimmune aetiology of the hypoparathyroidism in our patient was considered after her 165 
hypocalcaemia improved with glucocorticoid treatment. Autoimmune hypoparathyroidism is 166 
a major component of autoimmune polyglandular syndrome type 1 (APS1) along with chronic 167 
mucocutaneous candidiasis and primary adrenal insufficiency (Addison’s disease) [8-12]. 168 
APS1 commonly manifests in childhood and our patient presents with one of the major 169 
components. However, she does not fully adhere to an APS1 diagnosis as she does not display 170 
other symptoms currently. In addition, AIRE gene analysis in our patient did not identify 171 
typical known genetic mutations that cause APS1. However, there may be AIRE gene 172 
mutations not detected by our analysis and further in-depth mutational analysis is planned. 173 
IFN-ω antibodies are highly specific for APS1 [13,14]. Interestingly, our patient initially 174 
tested negative for IFN-ω antibodies, but proved positive on re-testing several months after 175 
her initial hypoparathyroidism diagnosis. This might suggest that she is progressing towards 176 
APS1 and may in time develop another major APS1 autoimmunity. Therefore, monitoring for 177 
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chronic mucocutaneous candidiasis and Addison’s disease would seem appropriate in the 178 
future. Considering an alternative APS diagnosis, there have been occasional reports of 179 
hypoparathyroidism occurring in other APS types [10, 11]. The patient does not conform to 180 
an APS2 (Addison’s disease, thyroid disease and/or type 1 diabetes) or APS3 (thyroid disease 181 
plus one other non-Addison’s disease autoimmunity) diagnosis. Thus APS4 (two or more 182 
autoimmune diseases not in APS types 1, 2 or 3) was considered. Our patient currently has 183 
two autoimmune diseases thus fulfils the criteria for APS4, however, as she matures, she may 184 
develop additional autoimmune endocrinopathies and her diagnosis might alter accordingly. 185 
In summary, our case report describes the presentation and diagnosis of a 10-year-old girl 186 
with hypoparathyroidism who subsequently developed SLE. We suggest that an autoimmune 187 
mechanism, potentially associated with an underlying genetic predisposition, is responsible 188 
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Figure legend 234 
 235 
Figure 1. The patient’s total serum calcium and plasma phosphate concentrations over time. 236 
Shading indicates the reference ranges (total serum calcium, 2.19-2.69 mmol/L; plasma 237 
phosphate, 3.4-6.2 mg/dL). The patient’s blood calcium levels were initially low 238 
(hypocalcaemia) and plasma phosphate levels were initially high (hyperphosphatemia), but 239 
both normalised following treatment with calcium and prednisone. The start-points of 240 
treatment with sevelamer (4.8 g/day) and prednisone (5 mg/day) are indicated.  241 
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Positive/negative Result Reference range 
Diabetes screening 




Negative 6.7 (index) ≤30 (index) 
Interferon-ω 
(07.03.2018) 
Negative <5 (index) <5 (index) 
Interferon-ω 
(27.06.2018) 
Positive 21.4 (index) <5 (index) 
21-hydroxylase  Negative <0.4 u/mL ≤0.4 u/mL 
Calcium-sensing 
receptor 
Negative 0.52 (index) 1.37 (index) 
Acetylcholine 
receptor 
Negative <0.45 nmol/L <0.45 nmol/L 
17-α-hydroxylase Negative <1 U/mL <1 U/mL 
Tissue 
transglutaminase 
Negative 0.4 U/mL <4 U/mL 
Thyroid peroxidase Negative 5.9 IU/mL <34 IU/mL 
Thyroglobulin Negative 13.6 IU/mL <115 IU/mL 
Thyroid-stimulating 
hormone receptor 
Negative 0.35 IU/L <1.75 IU/L 
  244 
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Learning points 245 
1. Hypoparathyroidism in children might be caused by an autoimmune process, damage to the 246 
parathyroid glands or a genetic disorder. 247 
2. The typical manifestations of the disease are hypocalcaemia and hyperphosphataemia that 248 
affect nerve and muscle functions leading to tetany, arrhythmias and seizures. 249 
3. Autoimmune hypoparathyroidism is often associated with other autoimmune diseases to 250 
constitute autoimmune polyglandular syndromes, typically APS1. 251 
4. The management of hypocalcaemia and hyperphosphatemia following decreased PTH 252 
concentrations involves supplementation with calcium and active forms of vitamin D. 253 
 254 
What is new? 255 
- The coexistence of hypoparathyroidism and SLE is extremely rare in children and is not 256 
typical for APS1. 257 
- The normalisation of calcium and phosphate blood concentrations after glucocorticoid 258 
treatment for SLE, reversed the symptoms of hypoparathyroidism indicating a possible 259 
autoimmune basis for the disease. 260 
  261 
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Figure 1 262 
 263 
 264 
